期刊
BLOOD
卷 113, 期 15, 页码 3600-3603出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-09-180695
关键词
-
类别
资金
- Deutsche Forschungsgemeinschaft (Bonn, Germany) [A1/B1]
- Interdisziplinares Zentrum fur Klinische Forschung
- University of Wuerzburg, Wuerzburg, Germany
- IZKF [E35]
- Flemish Fonds voor Wetenschappelijk Onderzoek (FWO
- Brussels, Belgium) [G.0299.06]
We recently demonstrated that blockade of the platelet adhesion receptor glycoprotein (GP) Ib alpha protects mice from ischemic stroke. Although von Willebrand factor (VWF) is the major ligand for GPIb alpha, GPIb alpha can engage other counterreceptors on endothelial cells, platelets, and leukocytes (eg, Mac-1 or P-selectin) potentially involved in stroke outcome. To further analyze whether VWF is of particular relevance for stroke development, VWF-/- mice underwent 60 minutes of middle cerebral artery occlusion. After 24 hours, VWF-/- mice had significantly smaller infarctions (P < .05) and less severe neurologic deficits (P < .01) compared with controls. This effect was sustained after 1 week, and intracranial bleeding was absent in VWF-/- mice as revealed by serial magnetic resonance imaging. Hydrodynamic injection of a VWF-encoding plasmid restored the susceptibility for stroke in VWF-/- mice. This study indicates that VWF is critically involved in cerebral ischemia. Hence, targeted inhibition of the GPIb alpha-VWF pathway might become a promising therapeutic option. (Blood. 2009; 113: 3600-3603)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据